Brexanolone is a drug indicated for the treatment of postpartum depression in adult women. Brexanolone received FDA approval in March 2019. It is the first drug to be specifically approved for postpartum depression. Postpartum depression is a severe condition which affects 10 to 20% of women worldwide. Clinically, it presents as significant depressive symptoms following delivery and often coexists with anxiety. Approximately 5 to 10% of these patients develop severe postpartum depression. Postpartum depression is one of the leading causes of maternal mortality and morbidity, which ultimately affects the cognitive, behavioral, emotional, and physical wellbeing of the mother, infant, and their siblings. Therefore, the FDA has granted brexanolone as a Breakthrough Therapy Designation for the treatment of postpartum depression.
Mechanism of action of brexanolone is not fully known. Brexanolone is an aqueous formulation of allopregnanolone. Allopregnanolone is a major metabolite of progesterone. Levels of allopregnanolone continue to rise with progesterone during pregnancy with the highest in the third trimester. Allopregnanolone is a potent, endogenous neuroactive steroid that modulates neuronal excitability through positive allosteric modulation on the synaptic and extrasynaptic gamma-aminobutyric acid (GABA) type A receptors. The extrasynaptic GABA type A receptors mediate tonic inhibition which makes allopregnanolone’s mechanism unique when compared to benzodiazepines which mediate the phasic inhibition at GABA type A receptors.
Brexanolone is only available through a restricted program called the Risk Evaluation and Mitigation Strategy Program. This program requires brexanolone to be administered intravenously at a certified health care facility under the close supervision of a health care provider. Patients are required to enroll in this program before drug administration. Brexanolone is administered as a continuous IV infusion over a total period of 60 hours, during approximately 2.5 days.
The prescribed dosing regimen is as follows:
If the patient does not tolerate the dose of 90 mcg/kg/hour, dose reduction to 60 mcg/kg/hour is the recommendation. Brexanolone is available as 100mg/20ml single-dose vials and requires dilution before administration.
Brexanolone exhibits dose-proportional pharmacokinetics over a dose range of 30 mcg/kg/hour to 270mg/kg/hour. After administration, brexanolone is extensively bound to plasma proteins, approximately 99% and has an elimination half-life of 9 hours. Brexanolone has a volume of distribution of 3L/kg, suggesting extensive distribution in tissues. Brexanolone is metabolized by extra-hepatic, non-CYP pathways mainly through, keto-reduction, glucuronidation, and sulfation; therefore, no dosage adjustment is necessary with hepatic impairment. Excretion is mostly in feces and urine, approximately 47% and 42% respectively, with the remaining 1% as unchanged brexanolone. The FDA prohibits the usage of brexanolone in patients who have an eGFR less than 15 mL/minute/1.73 m^2 due to the possible accumulation of solubilizing agent, betadex sulfobutyl ether sodium, in brexanolone.
Brexanolone transfers to breastmilk; however, the relative infant exposure to the drug is considered low. A concentration of less than 10ng/ml of brexanolone was present in breast milk 36 hours after the completion of infusion suggesting the maximum relative infant dose for brexanolone during the infusion was 1% to 2%.
Clinical trials have demonstrated brexanolone as generally well tolerated. Most common adverse effects associated with brexanolone are dizziness, sedation/somnolence, xerostomia, loss of consciousness, and hot flushes.
In patients whose symptoms of postpartum depression worsen or those who develop suicidal ideation or behavior, providers should consider changing the therapeutic regimen or stopping brexanolone completely.
At the highest recommended infusion rate of 90 mcg/kg/hour, brexanolone causes a minimal increase in the QTc interval.
No known contraindications are in the manufacturer’s labeling for brexanolone.
Continuous monitoring is necessary as brexanolone can cause excessive sedation and sudden loss of consciousness. Because of this, brexanolone is only available through the restricted distribution program. During infusion, patients need continuous monitoring with pulse oximetry and must be accompanied at all times by staff or family members while interacting with their children.
If patients experience hypoxia, infusion needs to be stopped immediately and should not be resumed. FDA has cautioned providers to monitor patients every 2 hours for sedative effects during non-sleep periods. In the case of excessive sedation or sudden loss of consciousness, dose interruption is recommended. Patients regain consciousness within 15 to 60 minutes of dose interruption. After recovery, infusion may be resumed at the same or lower dose as determined by the health care provider.
Patients are prohibited from driving or operating machinery until the sedative effects of the drug have entirely resolved.
Patients require close monitoring for worsening depression and suicidal thoughts or behaviors. In such cases, it is recommended to change the dosing regimen or discontinue brexanolone altogether. Concomitant use with central nervous system(CNS) depressants such benzodiazepines, alcohol, opioids, and antidepressants also requires close monitoring and/or avoidance of these agents.
Brexanolone has a rapid onset of action, within 60 hours of infusion and has a sustained response for up to 30 days after infusion. Patients in clinical trials were not followed after a 30 day follow-up period which limits data on toxicity on a long term basis. Long term efficacy of brexanolone, when compared with other antidepressants, is unknown and needs further research.
Limited clinical trial data is available concerning overdose. The manufacturer's labeling describes two cases of accidental overdose. These were due to infusion pump malfunction resulting in the sudden loss of consciousness. Patients recovered after 15 minutes of discontinuation without the need for supportive measures. The infusion was resumed, and patients completed treatment. It is recommended to stop the infusion immediately in case of overdose and initiate supportive measures as needed.
Postpartum depression presents as one of the most common complications after childbirth and can be a significant cause of suffering for the mother, infant, siblings, and their family. In the USA, the estimated prevalence of postpartum depression varies in states ranging from 8 to 20% with an overall mean prevalence of 11.5%. Postpartum depression affects at a multifactorial level resulting in maternal suicide, inability to work, child morbidity associated with impaired mother-infant bonding, and malnutrition within the first year of life. The longterm consequence of this disruptive parenting results in multiple adverse child outcomes, including increased risk for behavioral problems, lower mathematics grades, and development of depression. Therefore screening and early treatment for the postpartum depression is essential. Many women treated with selective serotonin reuptake inhibitors (SSRIs) for postpartum depression do not achieve adequate response or full remission of depressive symptoms. Therefore, an urgent need for therapy specifically designed for postpartum depression was needed.
Several studies have demonstrated the peripartum fluctuations in reproductive hormones, most importantly, allopregnanolone (the primary progesterone metabolite) play a pivotal role in the etiology of postpartum depression. Allopregnanolone is a potent positive allosteric modulator at the synaptic and extrasynaptic GABA type A receptors. Postulates are that the sudden decrease in the allopregnanolone levels after childbirth prevent the GABA type A receptors from adaptation resulting in triggering of the postpartum depression.
Since allopregnanolone has poor aqueous solubility, oral bioavailability and rapidly metabolized, an aqueous intravenous formulation, brexanolone, a proprietary of allopregnanolone, has been in development for the treatment of postpartum depression. To this date, one phase 2 and two phase 3 randomized, double-blind placebo-controlled trials have been conducted showing promising results of brexanolone in the treatment of postpartum depression. All clinical trials showed a substantial reduction in the Hamilton Rating Scale for Depression [HAM-D] at 60th hour when compared with the placebo; there was a rapid onset of action and sustained response during the treatment period with brexanolone. Rapid onset of action is essential as when postpartum patients receive treatment with SSRIs; it takes 4 to 6 weeks to achieve an adequate antidepressant response. Furthermore, the prompt onset of action determines the likelihood of near-term recovery and full remission of symptoms.
Most common adverse effects in phase 3 trials were headache, dizziness, and somnolence; therefore, close monitoring is required during infusion treatment with brexanolone. Although the incidence of dizziness and somnolence were higher in the brexanolone treatment group, the events were typically mild and did not require discontinuation of treatment. Currently, an ongoing phase 3 randomized, double-blind placebo-controlled trial is evaluating the efficacy and safety of brexanolone in the adolescent females (15 to 17 years of age) with postpartum depression.
Although these trials showed promising results, there are few limitations. Generalizability of brexanolone to the wider population is yet to be determined as the trials have focused on women with moderate to severe postpartum depression. No data exists on the effects of brexanolone after the completion of a 30-day follow up period. Need for a 60-hour intravenous infusion may be problematic for some patients because of logistic reasons. It would be interesting to see if an oral formulation of brexanolone with a similar efficacy is formulated or developed in the future.
Despite these limitations, brexanolone is the first therapeutic drug to be approved by the FDA, specifically for the treatment of postpartum depression. More large scale clinical trials are needed to determine the long-term safety and efficacy of brexanolone in the treatment of postpartum depression.
Administration of brexanolone requires the effort of an interprofessional team consisting of physicians, specialists, specialty-trained nurses, and pharmacists, communicating and collaborating to bring about the optimal therapeutic results in these cases. Pharmacy needs to verify the dosing and administraiton schedule, as well as check for potential drug-drug interactions, and let nursing know if any red flags are present. Nursing will adminsiter the medicaiton, and must watch for signs of intolerance or adverse reactions as the dose titrates upward, and inform the order clinician if they notice any issues, so therapy can be discontinued or modified. Only through this type of interprofessinoal teamwork can brexanolone be effective in treating post-partum depression. [Level V]
|||Schmied V,Johnson M,Naidoo N,Austin MP,Matthey S,Kemp L,Mills A,Meade T,Yeo A, Maternal mental health in Australia and New Zealand: a review of longitudinal studies. Women and birth : journal of the Australian College of Midwives. 2013 Sep; [PubMed PMID: 23583667]|
|||Shidhaye R,Mendenhall E,Sumathipala K,Sumathipala A,Patel V, Association of somatoform disorders with anxiety and depression in women in low and middle income countries: a systematic review. International review of psychiatry (Abingdon, England). 2013 Feb; [PubMed PMID: 23383668]|
|||Gavin NI,Gaynes BN,Lohr KN,Meltzer-Brody S,Gartlehner G,Swinson T, Perinatal depression: a systematic review of prevalence and incidence. Obstetrics and gynecology. 2005 Nov; [PubMed PMID: 16260528]|
|||Johannsen BM,Larsen JT,Laursen TM,Bergink V,Meltzer-Brody S,Munk-Olsen T, All-Cause Mortality in Women With Severe Postpartum Psychiatric Disorders. The American journal of psychiatry. 2016 Jun 1; [PubMed PMID: 26940804]|
|||Noorlander Y,Bergink V,van den Berg MP, Perceived and observed mother-child interaction at time of hospitalization and release in postpartum depression and psychosis. Archives of women's mental health. 2008; [PubMed PMID: 18270653]|
|||Luisi S,Petraglia F,Benedetto C,Nappi RE,Bernardi F,Fadalti M,Reis FM,Luisi M,Genazzani AR, Serum allopregnanolone levels in pregnant women: changes during pregnancy, at delivery, and in hypertensive patients. The Journal of clinical endocrinology and metabolism. 2000 Jul; [PubMed PMID: 10902789]|
|||Paul SM,Purdy RH, Neuroactive steroids. FASEB journal : official publication of the Federation of American Societies for Experimental Biology. 1992 Mar; [PubMed PMID: 1347506]|
|||Farrant M,Nusser Z, Variations on an inhibitory theme: phasic and tonic activation of GABA(A) receptors. Nature reviews. Neuroscience. 2005 Mar; [PubMed PMID: 15738957]|
|||Kanes S,Colquhoun H,Gunduz-Bruce H,Raines S,Arnold R,Schacterle A,Doherty J,Epperson CN,Deligiannidis KM,Riesenberg R,Hoffmann E,Rubinow D,Jonas J,Paul S,Meltzer-Brody S, Brexanolone (SAGE-547 injection) in post-partum depression: a randomised controlled trial. Lancet (London, England). 2017 Jul 29; [PubMed PMID: 28619476]|
|||Meltzer-Brody S,Colquhoun H,Riesenberg R,Epperson CN,Deligiannidis KM,Rubinow DR,Li H,Sankoh AJ,Clemson C,Schacterle A,Jonas J,Kanes S, Brexanolone injection in post-partum depression: two multicentre, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet (London, England). 2018 Sep 22; [PubMed PMID: 30177236]|
|||Timby E,Balgård M,Nyberg S,Spigset O,Andersson A,Porankiewicz-Asplund J,Purdy RH,Zhu D,Bäckström T,Poromaa IS, Pharmacokinetic and behavioral effects of allopregnanolone in healthy women. Psychopharmacology. 2006 Jun [PubMed PMID: 16177884]|
|||van Broekhoven F,Bäckström T,van Luijtelaar G,Buitelaar JK,Smits P,Verkes RJ, Effects of allopregnanolone on sedation in men, and in women on oral contraceptives. Psychoneuroendocrinology. 2007 Jun [PubMed PMID: 17470385]|
|||Navarro PA,Kaddouz D,de Ziegler D,Silva de Sá MF,Ferriani RA, Vaginal administration of allopregnanolone to postmenopausal women undergoing estrogen replacement therapy: preliminary results. Maturitas. 2003 Oct 20 [PubMed PMID: 14559386]|
|||Parsons CE,Young KS,Rochat TJ,Kringelbach ML,Stein A, Postnatal depression and its effects on child development: a review of evidence from low- and middle-income countries. British medical bulletin. 2012; [PubMed PMID: 22130907]|
|||Accortt EE,Cheadle AC,Dunkel Schetter C, Prenatal depression and adverse birth outcomes: an updated systematic review. Maternal and child health journal. 2015 Jun; [PubMed PMID: 25452215]|
|||Netsi E,Pearson RM,Murray L,Cooper P,Craske MG,Stein A, Association of Persistent and Severe Postnatal Depression With Child Outcomes. JAMA psychiatry. 2018 Mar 1; [PubMed PMID: 29387878]|
|||Molyneaux E,Telesia LA,Henshaw C,Boath E,Bradley E,Howard LM, Antidepressants for preventing postnatal depression. The Cochrane database of systematic reviews. 2018 Apr 18; [PubMed PMID: 29669175]|
|||Cox EQ,Sowa NA,Meltzer-Brody SE,Gaynes BN, The Perinatal Depression Treatment Cascade: Baby Steps Toward Improving Outcomes. The Journal of clinical psychiatry. 2016 Sep [PubMed PMID: 27780317]|
|||Schiller CE,Meltzer-Brody S,Rubinow DR, The role of reproductive hormones in postpartum depression. CNS spectrums. 2015 Feb; [PubMed PMID: 25263255]|
|||Osborne LM,Gispen F,Sanyal A,Yenokyan G,Meilman S,Payne JL, Lower allopregnanolone during pregnancy predicts postpartum depression: An exploratory study. Psychoneuroendocrinology. 2017 May; [PubMed PMID: 28278440]|
|||De Crescenzo F,Perelli F,Armando M,Vicari S, Selective serotonin reuptake inhibitors (SSRIs) for post-partum depression (PPD): a systematic review of randomized clinical trials. Journal of affective disorders. 2014 Jan [PubMed PMID: 24139299]|
|||van Calker D,Zobel I,Dykierek P,Deimel CM,Kech S,Lieb K,Berger M,Schramm E, Time course of response to antidepressants: predictive value of early improvement and effect of additional psychotherapy. Journal of affective disorders. 2009 Apr [PubMed PMID: 18849079]|
|||Jones I, Post-partum depression-a glimpse of light in the darkness? Lancet (London, England). 2017 Jul 29 [PubMed PMID: 28619475]|